PARP9

Across TCGA pan-cancer cohorts, PARP9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PARP9 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PARP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PARP9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

COAD, CCRCC, and GBM are the cancer types where PARP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Quartile	All	0.870	1.000	.015	18	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	17	view →
GBM	DFS	Tertile	All	0.624	0.797	.003	8	view →
HNSC	OS	Tertile	All	0.849	0.642	.015	4	view →
LUAD	DFS	Median	II,III,IV	0.711	0.374	.038	3	view →
LSCC	OS	Median	II,III,IV	0.611	0.856	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PARP9–COAD (DFS)

Open the COAD breakdown →